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ABSTRACT 
The aim of the present study was the in vitro evaluation and optimization of Ambroxol HCl sustained release matrix tablets by response surface methodology. 
The amounts of Methocel K4M and PVP K30 at three levels (-1, 0, +1) were selected as casual factors. In vitro dissolution time profiles at three different 
sampling times (1h, 4h, 8h) mean dissolution time (MDT) and time required for 50% drug release were selected as output variables . Thirteen kinds of 
Ambroxol HCl matrix tablets were prepared according to a 2
3 factorial design with five extra center points. The optimal tablet formulation based on some 
predetermined release criteria predicted by RSM was 80.28mg of Methocel K4M and 18.36mg of PVP K30. Dissolution studies were carried out in 900ml 0.1 
N HCl for 2 hours followed by 900 ml phosphate buffer (pH6.8) for subsequent 6 hours. Polynomial mathematical models, generated for various response 
variables using multiple linear regression analysis, were found to be statistically significant (p<0.05). The release mechanism was explored and explained by 
zero order,  first  order, Higuchi’s and  Korsmeyers’s  equation. The drug  release  followed both  diffusion and  erosion  mechanism  in all  cases. Calculated 
difference (f1 5) and similarity (f2 86) factors indicated that there was no difference between predicted and experimentally observed drug release profiles for 
the optimal formulation. It was concluded that optimization of Ambroxol HCl by Response Surface Methodology is quite efficient.  
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INTRODUCTION 
The  research  of  sustained-release  dosage  forms  is  an 
important  field  in  pharmaceutics.  In  the  last  few  decades, 
sustained-release  dosage  forms  have  made  significant 
progress in terms of clinical efficacy and patient compliance
1-
4. Oral sustained release dosage form by direct compression 
technique is a very simple approach of drug delivery systems 
that proved rational demand in the pharmaceutical arena as its 
ease,  compliance,  faster  production,  avoid  hydrolytic  or 
oxidative  reactions  occurred  during  processing  of  dosage 
forms . Sustained or controlled drug delivery  occurs while 
embedded with a polymer that may be natural or semisynthtic 
or synthetic in nature. The polymer is judiciously combined 
with the drug or other active ingredients in such a way that 
the active agent is released from the material in a predesigned 
fashion  and  released  the  drug  at  constant  rate  for  desired 
period
5. 
  There  are  a  number  of  techniques  applied  in  the 
formulation  as  well  as  in  the  manufacturing  of  sustained 
release  dosage  form  however  the  matrix  tablet  by  direct 
compression  has  attracted  much  attention  due  to  its 
technological simplicity in comparison with other controlled 
release systems. Direct compression method has been applied 
for preparation of tablet matrix that involved simple blending 
of  all  ingredients  used  in  the  formulations  and  then  under 
went direct compression. It required fewer unit operations, 
less  machinery,  reduced  number  of  personnel  and  reduced 
processing  time,  increased  product  stability  and  faster 
production  rate
6.  A  wide  array  of  polymers  has  been 
employed as drug retarding agents each of which presents a 
different approach to the matrix concept. Polymers belonging 
to hydrophilic matrix systems, when exposed to an aqueous 
medium,  does  not  disintegrate,  but  immediately  after 
hydration develops a highly viscous gelatinous surface barrier 
which  controls  the  drug  release  from  and  the  liquid 
penetration into the centre of the matrix system
7.
 
Ambroxol  is  a  metabolite  of  bromhexine
8.  It  is  an 
expectoration  improver  and  mucolytic  agent  used  in  the 
treatment of acute and chronic disorders characterized by the 
production  of  excess  or  thick mucus.  It  works  to  decrease 
mucus  viscosity  by  altering  its  structure.  Expectoration  of 
mucus  is  facilitated  and  breathing  is  eased  considerably. 
Long-term use is possible because of the good tolerability of 
the  preparation.  It  is  chemically  described  as  trans-4-((2-
Amino-3,  5-dibromobenzyl)  amino)  cyclohexanol.  It  is  a 
white  to  yellowish  crystalline  powder;  slightly  soluble  in 
water,  ethanol;  soluble  in  dimethylformamide,  methanol; 
insoluble in chloroform and benzene; melting point 240 C; 
administered orally. Its short biological half life (4 hours)
9 
that  calls  for  frequent  daily  dosing  (2  to  3  times)  and 
therapeutic use in chronic respiratory diseases necessitates its 
formulation  into  sustained  release  dosage  form.  So,  the 
development of sustained release dosage form of Ambroxol 
hydrochloride is of therapeutic relevance and can be used to 
provide a consistent dosage through sustaining an appropriate 
level of the drug over time. 
For  developing  a  sustained  release  tablet  dosage  form,  an 
important issue is to design an optimized formulation with an 
appropriate  dissolution  rate  in  a  short  time  period  and 
minimum  number  of  trials.  Many  statistical  experimental 
designs  have  been  recognized  as  useful  techniques  to 
optimize the process variables. For this purpose, a computer 
based  optimization  technique  with  a  response  surface 
methodology (RSM) utilizing a polynomial equation has been 
widely used. Different types of RSM designs include 3-level 
factorial  design,  central  composite  design  (CCD),  Box-
Behnken  design  and  D-optimal  design.  Response  surface 
methodology  (RSM)  is  use  when  only  a  few  significant 
factors are involved in optimization. The technique requires 
minimum experimentation and time, thus proving to be far 
more  effective  and  cost  effective  than  the  conventional 
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MATERIALS AND METHODS 
Materials 
Ambroxol hydrochloride was obtained from Alchymars ICM 
SM  Pvt.Ltd.,  India,  Hydroxy  propyl  methylcellulose 
(Methocel K4M) was a gift sample received from colorcon 
Asia  Pvt.Limited.  Microcrystalline  Cellulose  (MCC)  and 
PVP K30 (polyvinyl pyrrolidone K30) were purchased from 
Ming  Tai  Chemical  Co.Ltd.,  Taiwan.  Magnesium  stearate 
was procured from Hanua Chemicals Limited, Japan. 
Preparation of matrix tablets 
This  method  of  tablet  production  has  previously  been 
described  by  several authors
10,11 that  provided  reproducible 
experimental  results  in  terms  of  in  vitro  release.  Drug, 
polymer and other excipients were weighed separately for 20 
tablets per formulation as per proposed formulations (table: 
1). The proposed formulations were coded as K4M1, K4M2, 
K4M3,  K4M4,  K4M5,  K4M6,  K4M7,  K4M  8,  K4M9, 
K4M10, K4M11, K4M12 and K4M13. The amounts of drug 
and  excipients  are  expressed  in  milligram.  Then  active 
ingredient, microcrystalline cellulose (MCC), PVP K-30, and 
polymer were blended for 20 minutes and then magnesium 
stearate was added and further blended for another 2 minutes. 
Blended  mass  was  taken  in  the  hopper  and  then  die  and 
punch were adjusted to get the desired weight of the tablet 
(600 mg). The tablets were prepared by direct compression 
using  a  Perkin-Elmer  laboratory  hydraulic  press  equipped 
with a 11.7 mm flat faced punch and die set.  
Tablet assay and physical evaluation 
The tablets of the proposed formulations (K4M1 to K4M13) 
were  evaluated  for  hardness,  weight  variation,  thickness, 
friability and drug content. Hardness of the tablets was tested 
using a hand operated Monsanto hardness tester. Friability of 
the tablets was determined in a Roche friabilator (Campbell 
Electronics,  Mumbai).  The  thickness  of  the  tablets  was 
measured  by  vernier  calipers.    Weight  variation  test  was 
performed according to the official method. Drug content for 
Ambroxol hydrochloride was carried out by measuring the 
absorbance of the sample at 244.5 nm using Shimadzu 1240 
UV  spectrophotometer  and  comparing  the  content  from  a 
calibration  curve  prepared  with  standard  Ambroxol 
hydrochloride in the same medium. 
Design of experiment  
A  2
3  factorial  (central  composite)  design    with  α=1  was 
employed as per the standard protocol
12, 13. The amounts of 
HPMC K15M (X1) and PVP K 30 (X2) were selected as the 
factors, studied at 3 levels each. The central point (0, 0) was 
studied in quintuplicate. The range of  HMPC K4M (30-90 
mg)  and  PVPK30  (0-30  mg)  was  selected  based  on 
preformulation  trial  to  prepare  600  mg  ambroxol  HCl 
sustained release tablet. All other formulation and processing 
variables were kept invariant throughout the study. Tables (2-
3) summarize an account of the 13 experimental runs studied, 
their  factor  combinations  and  the  translation  of  the  coded 
levels to the experimental units employed during the study. 
Amount of drug released in 1 hour (rel1hr) (Y1), % of drug 
released in 4 hour (rel4hr) (Y2), % of drug released in 8 hour 
(rel8hr) (Y3), time to 50% drug release (t50%) (Y4) and MDT 
(Y5)  were  taken  as  the  response  variables.  The  response 
surface  graphs and mathematical models  were  obtained  by 
Design Expert
® 7.0 (Statease, USA) software. 
In vitro dissolution study of tablets 
Dissolution studies were conducted for a period of 8 hours 
according to USP method (USP XXII) using apparatus II at a 
speed of 100rpm and the temperature was maintained at 37 ± 
0.5° C. The dissolution studies were carried out in triplicate 
in  900  ml  0.1  N  HCl  for  2  hours  followed  by  900  ml 
phosphate buffer (pH 6.8) for subsequent 6 hours. At every 1-
hour  interval  samples  of  10  ml  were  withdrawn  from  the 
dissolution  medium  and  replaced  with  fresh  medium  to 
maintain the volume constant. After filtration and appropriate 
dilution, the sample solution was analyzed at 244.5 nm by a 
UV  spectrophotometer  (UV-1601,  Shimadzu,  Japan).  The 
amounts of drug present in the samples were calculated with 
the help of appropriate calibration curves constructed from 
reference standards. Drug dissolved at specified time periods 
was plotted as percent release versus time (hours) curve. 
Kinetic analysis of release data 
Different  kinetic  models  (zero-order,  first-order,  Higuchi’s 
and korsmeyer
’s) were applied to interpret the release profile 
from  matrix  system.  The  best  fit  with  higher  correlation 
(R
2>0.99) was found with the Higuchi’s equation. However, 
two factors diminish the applicability of Higuchi’s equation 
to matrix systems. This model fails to allow the influence of 
swelling of the matrix (upon hydration) and gradual erosion 
of the matrix. Therefore, the dissolution data were also fitted 
according  to  the  well-known  exponential  equation 
(Korsmeyer  equation),  Eq.  (1),  which  is  often  used  to 
describe the drug release behavior from polymeric systems
14. 
Log ( Mt / Mf ) = Log k + n Log t  …………. (1) 
Where, Mt is the amount of drug release at time t; Mf is the 
amount of drug release after infinite time; k is a release rate 
constant  incorporating  structural  and  geometric 
characteristics of the tablet; and n is the diffusional exponent 
indicative of the mechanism of drug release. Talukder et al 
applied this equation to evaluate the drug release mechanism 
from xanthan gum matrix tablets
15.  
To clarify the release exponent for different batches of matrix 
tablets,  the  log  value  of  percentage  drug  dissolved  was 
plotted  against  log  time  for  each  batch  according  to  the 
equation 1. A value of n = 0.45 indicates Fickian (case I) 
release; >0.45 but <0.89 for non-Fickian (anomalous) release; 
and  >0.89  indicates  super  case  II  type  of  release.  Case  II 
generally  refers  to  the  erosion  of  the  polymeric  chain  and 
anomalous transport (non-Fickian) refers to a combination of 
both diffusion and erosion controlled-drug release
16. 
Mean  dissolution  time  (MDT)  was  calculated  from 
dissolution  data  using the  following  equation  (Mockel  and 
Lippold)
17. 
MDT=( n / n+1 ).k -1/n ……………. (2) 
Analysis of similarity 
For every point of  observed/predicted drug release profiles 
for  optimal  formulation,  difference  (f1)  and  similarity  (f2) 
factors were calculated. According to the US Food and Drug 
Administration’s guide for industry
18generally f1 values up to 
15 (0-15) and f2 values greater than 50 ensures sameness of 
the  two  curves.  The  value  is  determined  by  the  following 
equation:  
 (6) 
Where n is the number of dissolution sample times, and Rt 
and Tt are the individual percentages dissolved at each time 
point  t  for  the  reference  and  test  dissolution  profiles 
respectively. 
RESULTS AND DISCUSSION 
Physical Evaluation of Ambroxol HCl matrix tablets 
The tablets of the proposed formulations (K4M1 to K4M13) 
were subjected to various evaluation tests such as thickness, 
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The thickness of the tablets ranged from 3.41 to 3.54 mm. 
The hardness and percentage friability  of the tablets of all 
batches ranged from 7.21 to 7.98 kg/cm
2 and 0.01 to 0.03%, 
respectively. The average percentage deviation of 20 tablets 
of  each  formula  was  less  than  ±5%.  Drug  content  among 
different batches of tablets ranged from 97.13 to 100.03%. 
Thus,  all  the  physical  parameters  of  the  matrices  were 
practically within control. 
Effect of Methocel K4M on release pattern of Ambroxol 
Hydrochloride matrix tablets 
For this experiment, different Methocel K4M matrix tablets 
containing ambroxol hydrochloride as active ingredient were 
prepared  according  to  formulation  shown  in  table  1.  The 
prepared tablets were subjected to in vitro dissolution studies 
in paddle method at 100 rpm in 900ml, 0.1N HCl medium at 
37
0 c (± 0.5
0c) for 2 hours followed by 900 ml,  phosphate 
buffer (pH 6.8) medium for another 6 hours at 37
0c (±0.5
0c). 
Three  tablets  from  each  formulation  were  used  for  the 
dissolution study. The release profile of Ambroxol HCl was 
monitored  up  to  8  hours.  To  determine  the  effects  of 
polymers on drug release, different kinetic models such as 
Zero  order,  First  order,  Korsmeyer,  Higuchi  were 
investigated.  The  zero  order,  First  order,  Higuchi  and 
Korsmeyer release patterns are shown in figure 1(A-D). The 
percent  of  drug  release  from  these  13  formulations  at 
different time intervals is shown in the table 4.  
From  the  graphs,  a  release  profile  of  ambroxol  HCl 
containing Methocel K4M matrix tablet of 13 formulations 
was obtained. The total % of ambroxol HCl release from the 
formulation  K4M1,  K4M2,  K4M3,  K4M4,  K4M5,  K4M6, 
K4M7,  K4M  8,  K4M9,  K4M10,  K4M11,  K4M12  and 
K4M13  were  94.35%,  92.14%,90.22%  88.24%,  85.41%, 
84.26%,81.85%, 80.53%, 77.99%, 87.06%, 86.42%, 85.89%, 
86.14%  respectively.  It  has  been  observed  that  the  release 
rate has been declined with the increase of polymer content. 
The highest percent of drug release within 8 hours is obtained 
from K4M1 where polymer content is 5%. But in K4M9, the 
polymer  content  is  15% ,  the release  of  drug  is  minimum 
77.99 % within 8 hours. The rate of drug release was found to 
be inversely related to the amount of Methocel K4M present 
in the matrix structure, i.e. the drug release increased with 
decrease in the polymer content of the matrix tablet. This is 
due to the formation of gel barrier of the hydrophilic HPMC 
polymer. Elevating  the  concentration  of  HPMC  may  result 
increased  tortuosity  or  gel  strength  of  the  polymer.  When 
HPMC polymer is exposed to aqueous medium, it undergoes 
rapid  hydration  and  chain  relaxation  to  form  viscous 
gelatinous layer  (gel layer). This is an agreement  with  the 
literature
19,20  findings  that  the  viscosity  of  the  gel  layer 
around  the  tablet  increases  with  increase  in  the  hydrogel 
concentration,  thus  limiting  the  release  of  the  active 
ingredient.  Failure  to  generate  a  uniform  and  coherent  gel 
may cause rapid drug release.   
In this experiment, the release kinetics data (table 5)  were 
treated  according  to  Higuchi’s  and  Korsmeyer  et  al.’s 
equations. The in vitro release profiles of drug from all these 
formulations could be best expressed by Higuchi’s equation, 
as the plots showed high linearity ( R
2: 0.992~0.997). From 
Higuchi model, it is evident that Ambroxol hydrochloride is 
released  by  diffusion  process.  To  confirm  the  diffusion 
mechanism, the data were fitted into Korsmeyer’s equation. 
The formulations showed good linearity (R
2: 0.990~0.998), 
with slope (n) values ranging from 0.546-0.615. This n value  
appears  to  indicate  a  coupling  of  diffusion  and  erosion 
mechanism (known as anomalous non-Fickian diffusion). 
The drug release also fitted first order kinetic model to high 
extent.  It  indicates  the  drug  release  is  dependent  on  the 
concentration of Ambroxol hydrochloride. 
The  mean  dissolution  time  (MDT)  of  K4M9  formulation 
figure 1(E) is highest (4.38 hrs), which means it can retard 
drug release most effectively.The values of t50% figure 1(F) 
enhanced markedly from 2.55 hrs, observed at low levels of 
both the variables, to as high as 3.82 hrs, observed at high 
levels  of  both  the  variables.  This  finding  indicated 
considerable release retarding potential of the polymer and 
binder.  
To determine possible interaction of two polymers a response 
surface study was also done. The drug release percentages at 
1hr,  4hrs,  8  hrs,  t50%  and  MDT  were  selected  as 
responses(table 4). These time periods are selected to detect 
any initial burst effect, t50% and t90%. From multiple regression 
analysis (table 6), it was found that Methocel K4M (X1) was 
responsible for reducing drug release significantly (p<0.05) at 
1, 4 and 8 hours. No Interaction between Methocel K4M and 
PVP  K  30  was  found  regarding  drug  release.  It  was  also 
found that PVP K 30 (X2) was responsible for reducing drug 
release significantly (p<0.05) at 1, 4 and 8 hours. 
Optimization 
Figure 2 (A to E) shows the three-dimensional diagrams of 
each response variable as a function of HPMC K4M and PVP 
K30 obtained by using RSM. The model was optimized by 
choosing  optimum  formulation  based  on  predetermined 
criteria  of  release  profile.  The  target  release  profile  was 
selected as 24%, 54% and 76% in 1h, 4h and 8 h respectively. 
The range of Methocel K4 M and PVP K 30 was set at 5-15% 
and 0-5% respectively. The optimization was carried out in 
Design Expert
® 7.0 software. Out of 39 solutions suggested 
by the software, the solution having highest desirability was 
selected. Tablets were prepared using 13.38% w/w Methocel 
K4M  and  3.06%  w/w  PVP  K  30  respectively.  Other 
excipients used were same as table-1. Tablets were prepared 
by direct compression method. The dissolution of optimized 
formulation  was  carried  out  by  the  method  described  in 
“Materials and Method” section. The f1 and f2 values were 
also calculated for each time point. The predicted and actual 
release were almost same (f1≥5 andf2≥86, Fig.:3). 
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Table1: Different formulations of Ambroxol  Hydrochloride tablet containing K4M formulations 
Formulation code 
Weight (mg)/ Tablet 
Ambroxol HCl  Methocel K4M CR  PVP K 30 
Magnesium 
Stearate  MCC 101  Total 
K4M1  75  30  00  3  492  600 
K4M2  75  30  15  3  477  600 
K4M3  75  30  30  3  462  600 
K4M4  75  60  00  3  462  600 
K4M5  75  60  15  3  447  600 
K4M6  75  60  30  3  432  600 
K4M7  75  90  00  3  432  600 
K4M8  75  90  15  3  417  600 
K4M9  75  90  30  3  402  600 
K4M10  75  60  15  3  447  600 
K4M11  75  60  15  3  447  600 
K4M12  75  60  15  3  447  600 
K4M13  75  60  15  3  447  600 
 
Table 2: Factor combinations as per the chosen experimental design 
Trial no.  Formulation code 
Coded Factor levels 
X1  X
2 
1  K4M1  -1  -1 
2  K4M2  -1  0 
3  K4M3  -1  1 
4  K4M4  0  -1 
5  K4M5  0  0 
6  K4M6  0  1 
7  K4M7  1  -1 
8  K4M8  1  0 
9  K4M9  1  1 
10  K4M10  0  0 
11  K4M11  0  0 
12  K4M12  0  0 
13  K4M13  0  0 
 
Table 3: Translation of coded levels for Methocel K4M  Formulations 
Coded level  -1  0  1 
X1(Methocel K4M )  5%  10%  15% 
X2 (PVPK30)  0%  2.5%  5% 
 
Table 4: The casual factor and responses of model formulations of Ambroxol HCl sustained release tablets of K4M formulations 
Trial  Formulation  X1  X2  Y1  Y2  Y3  Y4  Y5 
01  K4M1  -1  -1  28.44  66.15  94.35  2.55  3.11 
02  K4M2  -1  0  27.02  65.83  92.14  2.66  3.20 
03  K4M3  -1  1  26.91  63.73  90.22  2.75  3.35 
04  K4M4  0  -1  25.39  60.05  88.24  2.92  3.49 
05  K4M5  0  0  24.32  58.93  85.41  3.10  3.69 
06  K4M6  0  1  24.13  57.99  84.26  3.16  3.76 
07  K4M7  1  -1  22.88  54.53  81.85  3.44  4.07 
08  K4M8  1  0  22.15  54.14  80.53  3.54  4.19 
09  K4M9  1  1  19.54  52.38  77.99  3.82  4.38 
10  K4M10  0  0  25.05  59.31  87.06  3.10  3.70 
11  K4M11  0  0  24.15  58.44  86.42  3.11  3.68 
12  K4M12  0  0  23.99  59.05  85.89  3.16  3.72 
13  K4M13  0  0  24.31  57.89  86.14  3.14  3.72 
 
X1 and X2 are the amount of Mehocel K4M and PVP K 30 respectively. The formulations are according to table 1. Y: responses, the release percent at 1 h(Y1), 
4 h (Y2), 8 h (Y3), T 50%(Y4) and MDT (Y5). 
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Table 5: Release kinetics of Ambroxol HCl matrix tablets of K4M formulations 
Code 
Zero Order  First Order  Higuchi  Korsmeyer 
r
2  K0  r
2  K1  r
2  KH  r
2  n 
K4M1  0.933  10.818  0.964  -0.142  0.997  34.091  0.998  0.574 
K4M2 
0.931  10.676  0.984  -0.130  0.996  33.652  0.995  0.588 
K4M3 
0.930  10.343  0.987  -0.118  0.994  31.304  0.996  0.577 
K4M4 
0.933  10.220  0.992  -0.110  0.994  32.157  0.994  0.596 
K4M5 
0.937  9.921  0.996  -0.100  0.995  31.167  0.995  0.599 
K4M6 
0.938  9.844  0.998  -0.097  0.995  30.904  0.996  0.600 
K4M7 
0.946  9.487  0.996  -0.088  0.994  29.654  0.997  0.606 
K4M8 
0.944  9.306  0.994  -0.084  0.994  29.109  0.995  0.609 
K4M9 
0.947  9.104  0.997  -0.079  0.992  28.401  0.990  0.646 
K4M10 
0.944  10.012  0.987  -0.103  0.994  31.324  0.998  0.596 
K4M11 
0.944  10.012  0.993  -0.103  0.994  31.494  0.996  0.609 
K4M12 
0.947  10.084  0.995  -0.103  0.993  31.479  0.997  0.615 
K4M13 
0.943  10.006  0.993  -0.102  0.994  31.304  0.996  0.605 
 
Table 6: Regression equation for each response variable determined by Multiple regression analysis for K4M formulations 
Regression 
coefficient 
Independent 
variables  Y1  Y2  Y3  Y4    Y5 
b0    24.48308  59.10923  86.19231  3.111863  3.697534 
b1  X1  -2.96667  -5.77667  -6.05667  0.472107  0.495881 
b2  X2  -1.02167  -1.105  -1.995  0.136013  0.135654 
 
X1 and X2 are the amount of Mehocel K4M and PVP K 30 respectively. The formulations are according to table 1. Y: responses, the release percent at 1 h(Y1), 
4 h (Y2), 8 h (Y3), T 50%(Y4) and MDT (Y5). 
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Fig. 1A: Zero order plot of release kinetics of    Fig. 1B: First order plot of release kinetics of 
ambroxol HCl matrix tablets                      ambroxol HCl matrix tablets 
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Fig. 1C: Higuchi plot of release kinetics of          Fig. 1D: Korsmeyer plot of release kinetics of ambroxol HCl matrix tablets                          
ambroxol HCl matrix tablets 
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Fig.1E: MDT values of Methocel K4M  Fig. 1F: T50% values of Methocel K4M based matrix tablets 
based matrix tablets                           
   
 
 
Fig. 2A: Response surface plot of tablet                Fig. 2B: Response surface plot of tablet formulations after 1 hours 
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Fig. 2C: Response surface plot of tablet           Fig. 2D: Response surface plot of tablet formulations after 8 hours dissolution 
showing the effect of polymer on T50%   
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Fig.2E: Response surface plot of tablet                Fig. 3: Predicted and actual drug release from  
formulations showing the effect of polymer        optimized formulation 
on MDT 
 
CONCLUSION 
It  may  be  concluded  from  the  present  study  that  the 
hydrophilic  matrix  tablets  of  Ambroxol  hydrochloride, 
prepared  using  Methocel  K4M  and  PVP  K  30,  can 
successfully  be  employed  as  twice-a-day  oral  sustained 
release drug delivery system. Both the polymer and binder 
plays  major  role  for  the  sustained  release  of  Ambroxol 
hydrochloride.  However,  appropriate  balancing  between 
various  levels  of  the  polymer  and  binder  may  contribute 
better  results.  High  degree  of  prognosis  obtained  using 
Response  Surface  Methodology.  So,  optimization  of 
Ambroxol hydrochloride by Response Surface Methodology 
is quite efficient.  
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